The Latest Regenerative Medicine Articles from Streetwise Reports

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases

Streetwise Reports (07/02/2021)

Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. read more >

Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial

Streetwise Reports (06/28/2021)

Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis. read more >

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue

Streetwise Reports (05/07/2021)

Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. read more >

CryoLife Shares Trade 18% Higher on Q1 Financial Results

Streetwise Reports (04/30/2021)

Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million. read more >

Showing Results: 1 to 4 of 4

More Experts

"VIV entered an eight-year distribution agreement with AB Vista."

❭

– Joseph Gomes, Noble Capital Markets